Nov 18, 2013 8:05 AM PST
Companies developing treatments for Melanoma can be very profitable for investors
Nov 5, 2013 8:32 AM PST
As a long-term investor looking to invest across many sectors, biotechnology is one that is worth my extra research. The area I find myself most focused on within the biotechnology sector is, of course, cancer research. It may be because of the tremendous press...
Sep 25, 2013 6:40 AM PDT
Last year I wrote an article entitled, "Alternative Cancer Therapies Currently Overlooked By Investors", covering OncoSec Medical (ONCS.OB), Inovio Pharmaceuticals (INO), Dendreon Corp (DNDN) and Celgene (CELG). My main focus in that specific article were companies...
Aug 26, 2013 6:47 AM PDT
If the action from Inovio Pharmaceuticals Inc. (NYSEMKT:INO) is any clue, then Prana Biotechnology Limited (NASDAQ:PRAN) may be ready to make a sizable pullback.
Aug 6, 2013 11:47 AM PDT
OncoSec Medical (OTC: ONCS) and Inovio Pharmaceuticals (NYSE: INO) have been exceptional performers in recent trading due to investor excitement over electroporation technology and recent data that was presented that supports this process of drug delivery enhancement. In the last month alone, OncoSec moved up 44%. Inovio has moved up 213% on substantial volume. Since my last note, Oncosec has move about 15% higher while Inovio has doubled.
Jul 16, 2013 6:58 AM PDT
Recently presented data from a preclinical study performed using Inovio Pharmaceuticals’ (NYSE: INO) DNA vaccine against the H7N9 strain of avian influenza (bird flu) garnered some interest and buying momentum in INO, although investors seemed even more impressed after the release of the peer-reviewed publication analyzing the data from 2 Phase I trials for Inovio’s PENNVAX-B vaccine, which was delivered using Inovio’s CELLECTRA electroporation device. PENNVAX induced a strong T-cell response in 89% of the patients that had received three doses of the vaccine plus a signaling protein called Interleukin-12, inducing a best-in-class immune system response against HIV.
Jul 1, 2013 7:48 AM PDT
Inovio Pharmaceuticals Inc. (NYSEMKT:INO) has doled out some big gains of late, but this rally wasn't built to last.
Feb 6, 2013 6:12 AM PST
Inovio’s intrinsic value is hard to gauge at this point, because the majority of its pipeline is involved in a partnership and because all of the programs are in early stages of development. The market capitalization is about $100 million at this point, which isn’t cheap or expensive for the company’s current position. This is why I think INO might simply trade on sentimental shifts in the market as was the case throughout 2012.
Jan 18, 2013 12:27 PM PST
Vringo Inc (AMEX: VRNG) jumped up 7.37% to $3.35 on a traded volume of 2.91 million shares. The 52-week range for the stock is $0.68 and $5.73. The Company has Price/Sales ratio of 942.19 and Price/Book ratio of 2.24. The 50-Day Moving Average and 200-Day Moving...
Jan 15, 2013 11:52 AM PST
Aurizon Mines Ltd (USA) (AMEX: AZK) increased 1.75% to $4.66 on a traded volume of 4.54 million shares. The Company admits the announcement made on January 14, 2013 by Alamos Gold Incorporated of its commencement of an unsolicited bid for all of the issued...